{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:03:32Z","timestamp":1790492612090,"version":"4.1.0"},"reference-count":95,"publisher":"American Association for Cancer Research (AACR)","issue":"7","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08CA245181"],"award-info":[{"award-number":["K08CA245181"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 CA 009120"],"award-info":[{"award-number":["T32 CA 009120"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","award":["CRI14104"],"award-info":[{"award-number":["CRI14104"]}],"id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014549","name":"Stanford Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014549","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007185","name":"University of California, Los Angeles","doi-asserted-by":"publisher","award":["T32 Tumor Immunology Training program"],"award-info":[{"award-number":["T32 Tumor Immunology Training program"]}],"id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007186","name":"Jonsson Comprehensive Cancer Center, University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007186","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Neoadjuvant immune checkpoint blockade (ICB) and radiotherapy (RT) improve disease-free survival in select patients with soft-tissue sarcoma (STS). However, most STS are myeloid-rich and lack preexisting T cells associated with ICB response. In preclinical models, we observed that intratumoral BO-112 [nanoplexed polyinosinic: polycytidylic acid (poly I:C)] engages myeloid cells that persist after RT, ultimately enhancing T cell\u2013dependent tumor control. We evaluated BO-112 and hypofractionated RT, with or without nivolumab, in 14 patients with high-risk STS in a phase I neoadjuvant trial. Consistent with its immunologic potency, the triple combination induced rare immune-related adverse events (myositis\u2013myocarditis\u2013myasthenia gravis spectrum), mitigated by BO-112 and nivolumab dose adjustment. BO-112 and RT reprogrammed tumor-associated myeloid cells toward antigen-presenting states, promoted clonal replacement by less exhausted T cells, and enhanced malignant cell depletion compared with standard RT. These immunologic changes coincided with encouraging disease control in a small, high-risk cohort, supporting further clinical development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Intratumoral BO-112 and hypofractionated RT activate systemic T-cell immunity in mouse models and in a phase I neoadjuvant study of high-risk, resectable sarcoma. Engaging myeloid cells with BO-112 represents a potent strategy with RT to replete T cell\u2013deficient tumors and expand the benefits of neoadjuvant ICB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-25-1132","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T13:30:57Z","timestamp":1772717457000},"page":"1280-1303","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results"],"prefix":"10.1158","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0249-1969","authenticated-orcid":false,"given":"Jie","family":"Deng","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 1 Department of Radiation Oncology, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4555-589X","authenticated-orcid":false,"given":"Aastha","family":"Pal","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5632-5021","authenticated-orcid":false,"given":"Stefano","family":"Testa","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6547-7073","authenticated-orcid":false,"given":"Jingyu W.","family":"Xu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00f54p054","id-type":"ROR","asserted-by":"publisher"}],"name":"Stanford University 3 Division of Immunology and Rheumatology, Department of Medicine, , Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8597-643X","authenticated-orcid":false,"given":"Linh M.","family":"Tran","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 7 Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine, , Los Angeles, California."},{"name":"8Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4839-1250","authenticated-orcid":false,"given":"Danielle S.","family":"Graham","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 5 Division of Surgical Oncology, Department of Surgery, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8121-9301","authenticated-orcid":false,"given":"Aviv","family":"Hargil","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7892-886X","authenticated-orcid":false,"given":"Ajay","family":"Subramanian","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6491-4432","authenticated-orcid":false,"given":"Katie M.","family":"Campbell","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 6 Division of Hematology-Oncology, Department of Medicine, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8714-7221","authenticated-orcid":false,"given":"Sam","family":"Limsuwannarot","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4422-7639","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Chumpitaz Lavalle","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 1 Department of Radiation Oncology, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1988-880X","authenticated-orcid":false,"given":"Scott C.","family":"Chin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 1 Department of Radiation Oncology, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9563-4986","authenticated-orcid":false,"given":"Sarah","family":"Kremer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 1 Department of Radiation Oncology, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4159-7707","authenticated-orcid":false,"given":"Mito","family":"Tariveranmoshabad","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 1 Department of Radiation Oncology, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9101-2194","authenticated-orcid":false,"given":"Agnes","family":"Ewongwo","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6306-9203","authenticated-orcid":false,"given":"S.K. Nadia Rahman","family":"Silvia","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1541-3698","authenticated-orcid":false,"given":"Heather","family":"Ogana","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9323-8744","authenticated-orcid":false,"given":"Neda","family":"Nemat-Gorgani","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3656-8039","authenticated-orcid":false,"given":"Steven M.","family":"Dubinett","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 7 Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine, , Los Angeles, California."},{"name":"8Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0919-5679","authenticated-orcid":false,"given":"Jillian R.","family":"Jaycox","sequence":"additional","affiliation":[{"name":"9Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6586-3720","authenticated-orcid":false,"given":"Carol","family":"Felix","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 1 Department of Radiation Oncology, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5674-678X","authenticated-orcid":false,"given":"D\u00f6rthe","family":"Schaue","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 1 Department of Radiation Oncology, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8435-5065","authenticated-orcid":false,"given":"Scott D.","family":"Nelson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 10 Department of Pathology, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9181-2714","authenticated-orcid":false,"given":"Benjamin","family":"Levine","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 11 Department of Diagnostic Radiology, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3908-493X","authenticated-orcid":false,"given":"Kambiz","family":"Motamedi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 11 Department of Diagnostic Radiology, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5232-4938","authenticated-orcid":false,"given":"Varand","family":"Ghazikhanian","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 11 Department of Diagnostic Radiology, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2374-3320","authenticated-orcid":false,"given":"Bartosz","family":"Chmielowski","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 6 Division of Hematology-Oncology, Department of Medicine, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9150-7784","authenticated-orcid":false,"given":"Vishruth","family":"Reddy","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 1 Department of Radiation Oncology, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1633-7746","authenticated-orcid":false,"given":"Arun S.","family":"Singh","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 6 Division of Hematology-Oncology, Department of Medicine, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7541-9510","authenticated-orcid":false,"given":"Zuzana Jirakova","family":"Trnkova","sequence":"additional","affiliation":[{"name":"12Highlight Therapeutics S.L., Paterna, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2343-5771","authenticated-orcid":false,"given":"Zinaida","family":"Good","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00f54p054","id-type":"ROR","asserted-by":"publisher"}],"name":"Stanford University 3 Division of Immunology and Rheumatology, Department of Medicine, , Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8136-4491","authenticated-orcid":false,"given":"Marisol","family":"Quintero","sequence":"additional","affiliation":[{"name":"12Highlight Therapeutics S.L., Paterna, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9325-2909","authenticated-orcid":false,"given":"Joseph G.","family":"Crompton","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 5 Division of Surgical Oncology, Department of Surgery, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3338-5878","authenticated-orcid":false,"given":"Nicholas","family":"Bernthal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 13 Department of Orthopedic Surgery, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3336-9333","authenticated-orcid":false,"given":"Fritz C.","family":"Eilber","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 5 Division of Surgical Oncology, Department of Surgery, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7913-5351","authenticated-orcid":false,"given":"Everett J.","family":"Moding","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California."},{"name":"4Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8692-1457","authenticated-orcid":false,"given":"Anusha","family":"Kalbasi","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California."},{"name":"4Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"2026070103123671900_bib1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026070103123671900_bib2","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-19-1824","article-title":"Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab","volume":"26","author":"Keung","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026070103123671900_bib3","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1200\/JCO-24-02524","article-title":"Botensilimab (Fc-enhanced anti\u2013cytotoxic lymphocyte-association protein-4 antibody) plus balstilimab (anti\u2013PD-1 antibody) in patients with relapsed\/refractory metastatic sarcomas","volume":"43","author":"Wilky","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026070103123671900_bib4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"2026070103123671900_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/0284186X.2023.2172688","article-title":"Immune-cell infiltration in high-grade soft tissue sarcomas; prognostic implications of tumor-associated macrophages and B-cells","volume":"62","author":"Nystr\u00f6m","year":"2023","journal-title":"Acta Oncol"},{"key":"2026070103123671900_bib6","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s43018-024-00743-y","article-title":"Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy","volume":"5","author":"Subramanian","year":"2024","journal-title":"Nat Cancer"},{"key":"2026070103123671900_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41577-022-00737-w","article-title":"Myeloid cell-targeted therapies for solid tumours","volume":"23","author":"Goswami","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"2026070103123671900_bib8","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.3390\/cancers15245760","article-title":"Immune cells in the tumor microenvironment of soft tissue sarcomas","volume":"15","author":"Jumaniyazova","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026070103123671900_bib9","doi-asserted-by":"crossref","first-page":"2197370","DOI":"10.1080\/2162402X.2023.2197370","article-title":"Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic","volume":"12","author":"Alvarez","year":"2023","journal-title":"Oncoimmunology"},{"key":"2026070103123671900_bib10","doi-asserted-by":"crossref","first-page":"e005011","DOI":"10.1136\/jitc-2022-005011","article-title":"Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control","volume":"11","author":"Rodriguez-Ruiz","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026070103123671900_bib11","doi-asserted-by":"crossref","first-page":"e002953","DOI":"10.1136\/jitc-2021-002953","article-title":"Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy","volume":"9","author":"Alvarez","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026070103123671900_bib12","doi-asserted-by":"crossref","first-page":"eabb0152","DOI":"10.1126\/scitranslmed.abb0152","article-title":"Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma","volume":"12","author":"Kalbasi","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026070103123671900_bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s40425-019-0568-2","article-title":"Immunotherapeutic effects of intratumoral nanoplexed poly I:C","volume":"7","author":"Aznar","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026070103123671900_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13045-022-01377-2","article-title":"Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study","volume":"15","author":"Spalato-Ceruso","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026070103123671900_bib15","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1001\/jamaoncol.2023.4015","article-title":"Toll-like receptor 4 agonist injection with concurrent radiotherapy in patients with metastatic soft tissue sarcoma: a phase 1 nonrandomized controlled trial","volume":"9","author":"Seo","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026070103123671900_bib16","doi-asserted-by":"crossref","first-page":"101026","DOI":"10.1016\/j.waojou.2025.101026","article-title":"Repeated and alternate stimulations with dsRNA and SEB alter responses in macrophages and epithelial cells","volume":"18","author":"Choi","year":"2025","journal-title":"World Allergy Organ J"},{"key":"2026070103123671900_bib17","doi-asserted-by":"crossref","first-page":"eabb0391","DOI":"10.1126\/scitranslmed.abb0391","article-title":"Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors","volume":"12","author":"M\u00e1rquez-Rodas","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026070103123671900_bib18","doi-asserted-by":"crossref","first-page":"1383000","DOI":"10.3389\/fphar.2024.1383000","article-title":"Harnessing the cGAS-STING pathway to potentiate radiation therapy: current approaches and future directions","volume":"15","author":"Colangelo","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026070103123671900_bib19","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"2026070103123671900_bib20","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(24)01812-9","article-title":"Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial","volume":"404","author":"Mowery","year":"2024","journal-title":"Lancet"},{"key":"2026070103123671900_bib21","doi-asserted-by":"crossref","first-page":"113972","DOI":"10.1016\/j.ejca.2024.113972","article-title":"Reconciling the discrepancies in randomized data of combining immunotherapy and radiation therapy: not all radiotherapy is created equal","volume":"201","author":"Chang","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026070103123671900_bib22","doi-asserted-by":"crossref","first-page":"e002038","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?","volume":"9","author":"Demaria","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026070103123671900_bib23","doi-asserted-by":"crossref","first-page":"100808","DOI":"10.1016\/j.neo.2022.100808","article-title":"The paradox of radiation and T cells in tumors","volume":"31","author":"Gough","year":"2022","journal-title":"Neoplasia"},{"key":"2026070103123671900_bib24","doi-asserted-by":"crossref","first-page":"109935","DOI":"10.1016\/j.radonc.2023.109935","article-title":"Meta-analysis of 5-day preoperative radiotherapy for soft tissue sarcoma (5D-PREORTS)","volume":"190","author":"Cury","year":"2024","journal-title":"Radiother Oncol"},{"key":"2026070103123671900_bib25","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1158\/1078-0432.CCR-19-3524","article-title":"A phase II trial of 5-day neoadjuvant radiotherapy for patients with high-risk primary soft tissue sarcoma","volume":"26","author":"Kalbasi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026070103123671900_bib26","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/nm1602","article-title":"A spatially and temporally restricted mouse model of soft tissue sarcoma","volume":"13","author":"Kirsch","year":"2007","journal-title":"Nat Med"},{"key":"2026070103123671900_bib27","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/2326-6066.CIR-20-0586","article-title":"Hallmarks of resistance to immune-checkpoint inhibitors","volume":"10","author":"Karasarides","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2026070103123671900_bib28","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026070103123671900_bib29","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s43018-022-00450-6","article-title":"A phase I\/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC","volume":"3","author":"Darragh","year":"2022","journal-title":"Nat Cancer"},{"key":"2026070103123671900_bib30","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/cancers13020360","article-title":"Immune checkpoint inhibitory therapy in sarcomas: is there light at the end of the tunnel?","volume":"13","author":"Siozopoulou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026070103123671900_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5435\/00124635-200901000-00006","article-title":"Soft-tissue sarcoma","volume":"17","author":"Gilbert","year":"2009","journal-title":"J Am Acad Orthop Surg"},{"key":"2026070103123671900_bib32","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026070103123671900_bib33","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1245\/s10434-022-12762-z","article-title":"A randomized trial of pembrolizumab & radiotherapy versus radiotherapy in high-risk soft tissue sarcoma of the extremity (SU2C-SARC032)","volume":"30","author":"Saif","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"2026070103123671900_bib34","doi-asserted-by":"crossref","first-page":"100850","DOI":"10.1016\/j.adro.2021.100850","article-title":"Is 5 the new 25? long-term oncologic outcomes from a phase II, prospective, 5-fraction preoperative radiation therapy trial in patients with localized soft tissue sarcoma","volume":"7","author":"Bedi","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"2026070103123671900_bib35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40425-018-0317-y","article-title":"Incorporating radiation oncology into immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop","volume":"6","author":"Marciscano","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026070103123671900_bib36","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"key":"2026070103123671900_bib37","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"2026070103123671900_bib38","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"2026070103123671900_bib39","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(02)09292-9","article-title":"Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial","volume":"359","author":"O\u2019Sullivan","year":"2002","journal-title":"Lancet"},{"key":"2026070103123671900_bib40","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(22)00638-6","article-title":"Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial","volume":"23","author":"Guadagnolo","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026070103123671900_bib41","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026070103123671900_bib42","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026070103123671900_bib43","doi-asserted-by":"crossref","first-page":"100172","DOI":"10.1016\/j.crmeth.2022.100172","article-title":"High-throughput identification of autoantibodies that target the human exoproteome","volume":"2","author":"Wang","year":"2022","journal-title":"Cell Rep Methods"},{"key":"2026070103123671900_bib44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41577-023-00974-7","article-title":"TCRs and AI: the future is now","volume":"24","author":"Sim","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"2026070103123671900_bib45","doi-asserted-by":"crossref","first-page":"eadj5792","DOI":"10.1126\/sciimmunol.adj5792","article-title":"Structural principles of peptide-centric chimeric antigen receptor recognition guide therapeutic expansion","volume":"8","author":"Sun","year":"2023","journal-title":"Sci Immunol"},{"key":"2026070103123671900_bib46","doi-asserted-by":"crossref","first-page":"100758","DOI":"10.1016\/j.xpro.2021.100758","article-title":"A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses","volume":"2","author":"Bozkus","year":"2021","journal-title":"STAR Protoc"},{"key":"2026070103123671900_bib47","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1158\/1078-0432.CCR-19-3416","article-title":"The immunosuppressive niche of soft-tissue sarcomas is sustained by tumor-associated macrophages and characterized by intratumoral tertiary lymphoid structures","volume":"26","author":"Chen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026070103123671900_bib48","doi-asserted-by":"crossref","first-page":"e0183594","DOI":"10.1371\/journal.pone.0183594","article-title":"The MHC class II antigen presentation pathway in human monocytes differs by subset and is regulated by cytokines","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"2026070103123671900_bib49","doi-asserted-by":"crossref","first-page":"e007180","DOI":"10.1136\/jitc-2023-007180","article-title":"Single-cell sequencing on CD8+ TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer\/testis antigen in non-small cell lung cancer","volume":"11","author":"Komuro","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026070103123671900_bib50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41576-020-0229-9","article-title":"Transcriptional profiling of physically interacting cells","volume":"21","author":"Koch","year":"2020","journal-title":"Nat Rev Genet"},{"key":"2026070103123671900_bib51","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41587-020-0442-2","article-title":"Dissecting cellular crosstalk by sequencing physically interacting cells","volume":"38","author":"Giladi","year":"2020","journal-title":"Nat Biotechnol"},{"key":"2026070103123671900_bib52","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41586-025-09754-w","article-title":"Tumour-reactive heterotypic CD8 T cell clusters from clinical samples","volume":"649","author":"Ib\u00e1\u00f1ez-Molero","year":"2026","journal-title":"Nature"},{"key":"2026070103123671900_bib53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/1078-0432.CCR-16-0870","article-title":"Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma","volume":"23","author":"Kalbasi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026070103123671900_bib54","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ebiom.2019.08.067","article-title":"Role of CXCR3 signaling in response to anti-PD-1 therapy","volume":"48","author":"Han","year":"2019","journal-title":"EBioMedicine"},{"key":"2026070103123671900_bib55","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/archsurg.138.3.248","article-title":"Retroperitoneal sarcomas: grade and survival","volume":"138","author":"Ferrario","year":"2003","journal-title":"Arch Surg"},{"key":"2026070103123671900_bib56","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/bjc.2016.259","article-title":"Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines","volume":"115","author":"Salawu","year":"2016","journal-title":"Br J Cancer"},{"key":"2026070103123671900_bib57","first-page":"43","article-title":"Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction","volume":"4","author":"Qiu","year":"2023","journal-title":"Nat Cancer"},{"key":"2026070103123671900_bib58","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"key":"2026070103123671900_bib59","doi-asserted-by":"crossref","first-page":"18490","DOI":"10.1073\/pnas.0809242105","article-title":"An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer","volume":"105","author":"Weichselbaum","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070103123671900_bib60","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1158\/1078-0432.CCR-21-4239","article-title":"Neoadjuvant therapy induces a potent immune response to sarcoma, dominated by myeloid and B cells","volume":"28","author":"Goff","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026070103123671900_bib61","doi-asserted-by":"crossref","first-page":"eadd7446","DOI":"10.1126\/sciimmunol.add7446","article-title":"Rapid recruitment and IFN-I-mediated activation of monocytes dictate focal radiotherapy efficacy","volume":"8","author":"Tadepalli","year":"2023","journal-title":"Sci Immunol"},{"key":"2026070103123671900_bib62","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1158\/2326-6066.CIR-18-0633","article-title":"CCR2-dependent recruitment of tregs and monocytes following radiotherapy is associated with TNF\u03b1-mediated resistance","volume":"7","author":"Mondini","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"2026070103123671900_bib63","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/s41467-017-01566-5","article-title":"Host STING-dependent MDSC mobilization drives extrinsic radiation resistance","volume":"8","author":"Liang","year":"2017","journal-title":"Nat Commun"},{"key":"2026070103123671900_bib64","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1158\/0008-5472.CAN-12-3981","article-title":"CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer","volume":"73","author":"Xu","year":"2013","journal-title":"Cancer Res"},{"key":"2026070103123671900_bib65","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1158\/1078-0432.CCR-15-3026","article-title":"Blocking indolamine-2,3-dioxygenase rebound immune suppression boosts antitumor effects of radio-immunotherapy in murine models and spontaneous canine malignancies","volume":"22","author":"Monjazeb","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026070103123671900_bib66","doi-asserted-by":"crossref","first-page":"2395067","DOI":"10.1080\/2162402X.2024.2395067","article-title":"Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade","volume":"13","author":"Rwandamuriye","year":"2024","journal-title":"Oncoimmunology"},{"key":"2026070103123671900_bib67","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/ijc.28711","article-title":"A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models","volume":"135","author":"Adlard","year":"2014","journal-title":"Int J Cancer"},{"key":"2026070103123671900_bib68","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/1078-0432.361.11.1","article-title":"Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy","volume":"11","author":"Mason","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2026070103123671900_bib69","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1158\/0008-5472.CAN-04-0926","article-title":"CpG oligodeoxynucleotide enhances tumor response to radiation","volume":"64","author":"Milas","year":"2004","journal-title":"Cancer Res"},{"key":"2026070103123671900_bib70","doi-asserted-by":"crossref","first-page":"e178767","DOI":"10.1172\/jci.insight.178767","article-title":"Enhancing radiotherapy response via intratumoral injection of a TLR9 agonist in autochthonous murine sarcomas","volume":"9","author":"Su","year":"2024","journal-title":"JCI Insight"},{"key":"2026070103123671900_bib71","doi-asserted-by":"crossref","first-page":"e432234","DOI":"10.1200\/EDBK_432234","article-title":"Immunotherapy in sarcoma: current data and promising strategies","volume":"44","author":"Wood","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026070103123671900_bib72","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","article-title":"Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy","volume":"24","author":"Marciscano","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026070103123671900_bib73","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1038\/s41467-022-34676-w","article-title":"Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors","volume":"13","author":"Darragh","year":"2022","journal-title":"Nat Commun"},{"key":"2026070103123671900_bib74","doi-asserted-by":"crossref","first-page":"17324","DOI":"10.1038\/s41598-021-96467-5","article-title":"Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data","volume":"11","author":"Makunts","year":"2021","journal-title":"Sci Rep"},{"key":"2026070103123671900_bib75","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-024-08105-5","article-title":"Immune responses in checkpoint myocarditis across heart, blood and tumour","volume":"636","author":"Blum","year":"2024","journal-title":"Nature"},{"key":"2026070103123671900_bib76","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/stem.596","article-title":"Concise review: mesenchymal tumors: when stem cells go mad","volume":"29","author":"Mohseny","year":"2011","journal-title":"Stem Cells"},{"key":"2026070103123671900_bib77","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1084\/jem.184.2.441","article-title":"Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens","volume":"184","author":"Dudley","year":"1996","journal-title":"J Exp Med"},{"key":"2026070103123671900_bib78","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1038\/s41467-019-11906-2","article-title":"Tumor-reprogrammed resident T cells resist radiation to control tumors","volume":"10","author":"Arina","year":"2019","journal-title":"Nat Commun"},{"key":"2026070103123671900_bib79","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev-immunol-082223-044122","article-title":"Molecular mechanisms governing CD8 T cell differentiation and checkpoint inhibitor response in cancer","volume":"43","author":"Rausch","year":"2025","journal-title":"Annu Rev Immunol"},{"key":"2026070103123671900_bib80","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026070103123671900_bib81","doi-asserted-by":"crossref","first-page":"eadf4919","DOI":"10.1126\/sciimmunol.adf4919","article-title":"Noncanonical MAVS signaling restrains dendritic cell-driven antitumor immunity by inhibiting IL-12","volume":"8","author":"Wu","year":"2023","journal-title":"Sci Immunol"},{"key":"2026070103123671900_bib82","doi-asserted-by":"crossref","first-page":"26496","DOI":"10.18632\/oncotarget.8420","article-title":"Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs","volume":"7","author":"Ranoa","year":"2016","journal-title":"Oncotarget"},{"key":"2026070103123671900_bib83","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/eji.202049158","article-title":"Tumor cell-intrinsic RIG-I signaling governs synergistic effects of immunogenic cancer therapies and checkpoint inhibitors in mice","volume":"51","author":"Poeck","year":"2021","journal-title":"Eur J Immunol"},{"key":"2026070103123671900_bib84","doi-asserted-by":"crossref","first-page":"E484","DOI":"10.1073\/pnas.1323253111","article-title":"RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation","volume":"111","author":"Widau","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070103123671900_bib85","doi-asserted-by":"crossref","first-page":"38235","DOI":"10.18632\/oncotarget.9428","article-title":"Accumulation of RNA-dependent protein kinase (PKR) in the nuclei of lung cancer cells mediates radiation resistance","volume":"7","author":"Hao","year":"2016","journal-title":"Oncotarget"},{"key":"2026070103123671900_bib86","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070103123671900_bib87","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026070103123671900_bib88","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"2026070103123671900_bib89","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ccell.2025.03.005","article-title":"Neoadjuvant immune checkpoint therapy: enabling insights into fundamental human immunology and clinical benefit","volume":"43","author":"Pauken","year":"2025","journal-title":"Cancer Cell"},{"key":"2026070103123671900_bib90","doi-asserted-by":"crossref","first-page":"e010074","DOI":"10.1136\/jitc-2024-010074","article-title":"Neoadjuvant immunotherapy in the evolving landscape of sarcoma treatment","volume":"12","author":"Cai","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026070103123671900_bib91","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070103123671900_bib92","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1158\/1078-0432.CCR-23-0250","article-title":"Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis","volume":"29","author":"Bui","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026070103123671900_bib93","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","article-title":"Integrating genomic features for non-invasive early lung cancer detection","volume":"580","author":"Chabon","year":"2020","journal-title":"Nature"},{"key":"2026070103123671900_bib94","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1158\/0008-5472.CAN-24-3281","article-title":"Evolutionary pressures shape undifferentiated pleomorphic sarcoma development and radiotherapy response","volume":"85","author":"Blomain","year":"2025","journal-title":"Cancer Res"},{"key":"2026070103123671900_bib95","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1158\/2326-6066.CIR-19-0401","article-title":"pVACtools: a computational toolkit to identify and visualize cancer neoantigens","volume":"8","author":"Hundal","year":"2020","journal-title":"Cancer Immunol Res"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-25-1132\/3745037\/cd-25-1132.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-25-1132\/3802931\/cd-25-1132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/7\/1280\/3807898\/cd-25-1132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/7\/1280\/3807898\/cd-25-1132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:42:53Z","timestamp":1782895373000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/7\/1280\/786255\/Neoadjuvant-BO-112-and-Hypofractionated-Radiation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":95,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,3,5]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-25-1132","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.32845894","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32845861","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32845873","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32845852","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32845885","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32845864","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32845876","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32845897","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32845900","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32845855","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32845888","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32845867","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32845891","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32845879","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32845849","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.8568787","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]}}}